Investigating how a protein helps the body sense and respond to airborne allergens
Official title: Cell surface LMAN1 as a General Sensor and Negative Regulator of Mannosylated Aeroallergens
Funded at University of Central Florida · NIH-11079541 · Data updated 2026-11-12
This study is looking at how a protein called LMAN1 helps the body recognize allergens in the air that can cause asthma symptoms, with the hope of finding new ways to prevent or treat asthma for those who are sensitive to these triggers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project start | July 1, 2022 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $342,986 |
| NIH project number | 5R01HL162897-04 |
| Project ID | NIH-11079541 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced allergic reactions or asthma symptoms related to airborne allergens.
✕Less likely to help
Patients who do not have allergies or asthma may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called LMAN1 in recognizing airborne allergens, which can trigger asthma symptoms. By studying how LMAN1 interacts with these allergens in the airway, researchers aim to uncover the mechanisms behind allergic responses and asthma development. The project involves laboratory experiments to analyze how LMAN1 functions as a receptor and its impact on immune responses. This could lead to new insights into preventing or treating asthma in sensitized individuals.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing or managing asthma triggered by airborne allergens.
How similar studies have gone: Other research has shown promising results in understanding immune responses to allergens, making this approach a continuation of established scientific inquiry.
Where this research is happening
-
University of Central Florida
Orlando, United States Active
Researchers
- Principal investigator: Tigno-Aranjuez, Justine Tiglao — University of Central Florida
- Study coordinator: Tigno-Aranjuez, Justine Tiglao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.